These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 3124027)

  • 41. Selegiline in the treatment of daily fluctuations in disability of parkinsonian patients with long-term levodopa treatment.
    Heinonen EH; Rinne UK; Tuominen J
    Acta Neurol Scand Suppl; 1989; 126():113-8. PubMed ID: 2515716
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Parkinson Study Group.
    Ann Neurol; 1998 Mar; 43(3):318-25. PubMed ID: 9506548
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease.
    Golbe LI; Lieberman AN; Muenter MD; Ahlskog JE; Gopinathan G; Neophytides AN; Foo SH; Duvoisin RC
    Clin Neuropharmacol; 1988 Feb; 11(1):45-55. PubMed ID: 3127050
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group.
    Ann Neurol; 1996 Jan; 39(1):37-45. PubMed ID: 8572664
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Deprenyl in Parkinson's disease.
    Lancet; 1982 Sep; 2(8300):695-6. PubMed ID: 6126632
    [No Abstract]   [Full Text] [Related]  

  • 46. MAO-B-Inhibitor selegiline (R-(-)-deprenyl). A new therapeutic concept in the treatment of Parkinson's disease. Proceedings of the international symposium. Berlin, January 23-25, 1987.
    J Neural Transm Suppl; 1987; 25():1-197. PubMed ID: 3123595
    [No Abstract]   [Full Text] [Related]  

  • 47. Deprenyl for the treatment of early Parkinson's disease.
    N Engl J Med; 1990 May; 322(21):1526-8. PubMed ID: 2110624
    [No Abstract]   [Full Text] [Related]  

  • 48. Multicenter trial of L-Deprenyl in Parkinson disease.
    Ruggieri S; Denaro A; Meco G; Carta A; Stocchi F; Agnoli A
    Ital J Neurol Sci; 1986 Feb; 7(1):133-7. PubMed ID: 3082793
    [TBL] [Abstract][Full Text] [Related]  

  • 49. L-deprenyl treatment of on-off phenomena in Parkinson's disease.
    Rinne UK; Siirtola T; Sonninen V
    J Neural Transm; 1978; 43(3-4):253-62. PubMed ID: 745018
    [No Abstract]   [Full Text] [Related]  

  • 50. Effect of deprenyl on the progression of disability in early Parkinson's disease.
    Parkinson Study Group
    N Engl J Med; 1989 Nov; 321(20):1364-71. PubMed ID: 2509910
    [TBL] [Abstract][Full Text] [Related]  

  • 51. (-)Deprenyl in the treatment of Parkinson's disease.
    Birkmayer W; Riederer P; Youdim MB
    Clin Neuropharmacol; 1982; 5(2):195-230. PubMed ID: 6814755
    [No Abstract]   [Full Text] [Related]  

  • 52. [Deprenyl as a co-adjuvant in the treatment of Parkinson disease].
    Ferrari E; Cacudi N; de Mari M; Iliceto G; Lamberti P
    Acta Neurol (Napoli); 1986 Aug; 8(4):455-61. PubMed ID: 3096087
    [No Abstract]   [Full Text] [Related]  

  • 53. The effect of R-(-)-deprenyl in de novo parkinsonian patients pretreated with levodopa and decarboxylase inhibitor correlated to depression and MHPG, HIAA and HVA levels in the cerebrospinal fluid.
    Przuntek H; Kuhn W; Kraus P
    Acta Neurol Scand Suppl; 1989; 126():153-6. PubMed ID: 2482649
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP). Parkinson Study Group.
    Shoulson I
    Acta Neurol Scand Suppl; 1989; 126():171-5. PubMed ID: 2515723
    [TBL] [Abstract][Full Text] [Related]  

  • 55. New approaches in the use of selegiline for the treatment of Parkinson's disease.
    Lees AJ; Frankel J; Eatough V; Stern GM
    Acta Neurol Scand Suppl; 1989; 126():139-45. PubMed ID: 2515719
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort.
    Marras C; McDermott MP; Rochon PA; Tanner CM; Naglie G; Rudolph A; Lang AE;
    Neurology; 2005 Jan; 64(1):87-93. PubMed ID: 15642909
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study.
    Waters CH; Sethi KD; Hauser RA; Molho E; Bertoni JM;
    Mov Disord; 2004 Apr; 19(4):426-32. PubMed ID: 15077240
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Parkinson Study Group.
    Ann Neurol; 1996 Jan; 39(1):29-36. PubMed ID: 8572663
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Big first scored with nerve diseases.
    Lewin R
    Science; 1989 Aug; 245(4917):467-8. PubMed ID: 2502841
    [No Abstract]   [Full Text] [Related]  

  • 60. Double-blind controlled study of pergolide mesylate as an adjunct to Sinemet in the treatment of Parkinson's disease.
    Olanow CW; Alberts MJ
    Adv Neurol; 1987; 45():555-60. PubMed ID: 3548266
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.